Medical Use of Cannabis Tied to Higher Prevalence of Cannabis Use Disorder
By Lori Solomon HealthDay Reporter
THURSDAY, Jan. 23, 2025 -- Adults aged 18 to 49 years reporting medical-only or medical-nonmedical cannabis use may have a higher prevalence of cannabis use disorder (CUD) than those reporting nonmedical only, according to a research letter published online Jan. 22 in JAMA Psychiatry.
Beth Han, M.D., Ph.D., M.P.H., from the National Institutes of Health in Bethesda, Maryland, and colleagues examined differences in cannabis use frequency and CUD prevalence for medical-only and medical-nonmedical versus nonmedical-only use among U.S. adults aged 18 to 49 years. The analysis included data from 72,668 participants in the 2021 to 2022 National Surveys on Drug Use and Health.
The researchers found that 29.5 percent of respondents reported past-year cannabis use: 83.7 percent for nonmedical-only use, 9.2 percent medical-only use, and 5.7 percent for medical-nonmedical use. More than one-third (34.8 percent) had CUD. A higher adjusted prevalence of severe, moderate, and mild CUD was seen among men and women aged 18 to 34 years and men aged 35 to 49 years reporting medical-only or medical-nonmedical use versus those reporting nonmedical-only use. Adults reporting medical-only or medical-nonmedical use had more days of cannabis use than those reporting nonmedical-only use.
"Clinicians should consider addiction risk before recommending medical cannabis and, if they do, should monitor for CUD emergence," the authors write.
One author disclosed having long-term stocks with relevant companies.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-01-25 00:00
Read more
- Access to Medical Test Results Is Confusing, Anxiety-Provoking
- Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
- Lower Dexamethasone Dose Does Not Impair Survival in Multiple Myeloma
- FDA Formaldehyde Ban in Hair Products on Hold Once Again
- FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
- Participation in National Diabetes Prevention Program Is Cost-Saving
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions